MedTrace Logo

The Effects of Cannabidiol and ∆-9-THC in Humans

NCT01180374 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2022-01-31

No results posted yet for this study

Summary

Cannabis is the most commonly used illicit substance in the US and herbal cannabis consists of a number of cannabinoids including Δ-9 THC and CBD. This study will characterize the interactive effects of the two major components of cannabis i.e. Δ-9-THC and CBD.

Conditions

  • Healthy

Interventions

DRUG

Cannabidiol

Active Cannabidiol 5mg.

DRUG

Delta-9-THC

Active Delta-9-THC (0.035mg/Kg) given intravenously over 20 minutes. The dose of THC that you may receive is a small dose and is roughly equivalent to smoking approximately one half to one whole marijuana cigarette, or "joint".

DRUG

Placebo

Placebo (about a quarter spoon of alcohol with no CBD).

DRUG

Placebo

Placebo (about a quarter spoon of alcohol with no THC) given intravenously over 20 minutes.

Sponsors & Collaborators

  • Yale University

    lead OTHER

Principal Investigators

  • Mohini Ranganathan, M.D · Yale University Medical School

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-02-01
Primary Completion
2014-10-06
Completion
2014-10-06

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01180374 on ClinicalTrials.gov